Novo Nordisk announced on Monday (November 17) that it is reducing prices for its popular obesity and diabetes drugs , Wegovy and Ozempic, for cash-paying patients. This move comes as the company faces increased competition in the weight loss market and pressure from President Donald Trump . The new pricing strategy aims to attract Americans willing to purchase medications directly from Novo Nordisk, bypassing insurance.

The company is offering the first two monthly doses of Wegovy and Ozempic for $199 , with the discount expiring at the end of March. Afterward, prices for self-pay patients will be reduced to $349 a month, down from $499. However, the 2-milligram dose of Ozempic will remain at $499. These discounts are available through Novo Nordisk's direct-to-consumer channels and

See Full Page